Abstract
The choice for the best antiretroviral scheme for HIV-1 infection reduces viral replication in patients undergoing treatment and, consequently, decreases the chances for the emergence of viral mutation. It also prevents the selection of resistant mutants, which leads to successful treatment. The efficacy of the therapeutic scheme can be evaluated by the reduction in the HIV plasma viral l…